Global Neuroendocrine Tumor Drug Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Neuroendocrine Tumor Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Tumor Drug.
The Neuroendocrine Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neuroendocrine Tumor Drug Segment by Company
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Eisai
Neuroendocrine Tumor Drug Segment by Type
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Somatostatin Receptor Antagonists
Others
Neuroendocrine Tumor Drug Segment by Application
Hospital
Clinic
Others
Neuroendocrine Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Neuroendocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Neuroendocrine Tumor Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Tumor Drug.
The Neuroendocrine Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neuroendocrine Tumor Drug Segment by Company
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Eisai
Neuroendocrine Tumor Drug Segment by Type
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Somatostatin Receptor Antagonists
Others
Neuroendocrine Tumor Drug Segment by Application
Hospital
Clinic
Others
Neuroendocrine Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Neuroendocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
110 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Neuroendocrine Tumor Drug Market Size Estimates and Forecasts (2020-2031)
- 1.2.2 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts (2020-2031)
- 1.3 Neuroendocrine Tumor Drug Market by Type
- 1.3.1 mTOR Protein Inhibitors
- 1.3.2 Tyrosine Kinase 3 Inhibitors
- 1.3.3 Growth Hormone Releasing Factor Antagonists
- 1.3.4 Somatostatin Receptor Agonists
- 1.3.5 Somatostatin Receptor Antagonists
- 1.3.6 Others
- 1.4 Global Neuroendocrine Tumor Drug Market Size by Type
- 1.4.1 Global Neuroendocrine Tumor Drug Market Size Overview by Type (2020-2031)
- 1.4.2 Global Neuroendocrine Tumor Drug Historic Market Size Review by Type (2020-2025)
- 1.4.3 Global Neuroendocrine Tumor Drug Forecasted Market Size by Type (2026-2031)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Neuroendocrine Tumor Drug Sales Breakdown by Type (2020-2025)
- 1.5.2 Europe Neuroendocrine Tumor Drug Sales Breakdown by Type (2020-2025)
- 1.5.3 Asia-Pacific Neuroendocrine Tumor Drug Sales Breakdown by Type (2020-2025)
- 1.5.4 South America Neuroendocrine Tumor Drug Sales Breakdown by Type (2020-2025)
- 1.5.5 Middle East and Africa Neuroendocrine Tumor Drug Sales Breakdown by Type (2020-2025)
- 2 Global Market Dynamics
- 2.1 Neuroendocrine Tumor Drug Industry Trends
- 2.2 Neuroendocrine Tumor Drug Industry Drivers
- 2.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
- 2.4 Neuroendocrine Tumor Drug Industry Restraints
- 3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Neuroendocrine Tumor Drug Revenue (2020-2025)
- 3.2 Global Top Players by Neuroendocrine Tumor Drug Sales (2020-2025)
- 3.3 Global Top Players by Neuroendocrine Tumor Drug Price (2020-2025)
- 3.4 Global Neuroendocrine Tumor Drug Industry Company Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Neuroendocrine Tumor Drug Major Company Production Sites & Headquarters
- 3.6 Global Neuroendocrine Tumor Drug Company, Product Type & Application
- 3.7 Global Neuroendocrine Tumor Drug Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Neuroendocrine Tumor Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Neuroendocrine Tumor Drug Players Market Share by Revenue in 2024
- 3.8.3 2023 Neuroendocrine Tumor Drug Tier 1, Tier 2, and Tier 3
- 4 Neuroendocrine Tumor Drug Regional Status and Outlook
- 4.1 Global Neuroendocrine Tumor Drug Market Size and CAGR by Region: 2020 VS 2024 VS 2031
- 4.2 Global Neuroendocrine Tumor Drug Historic Market Size by Region
- 4.2.1 Global Neuroendocrine Tumor Drug Sales in Volume by Region (2020-2025)
- 4.2.2 Global Neuroendocrine Tumor Drug Sales in Value by Region (2020-2025)
- 4.2.3 Global Neuroendocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2020-2025)
- 4.3 Global Neuroendocrine Tumor Drug Forecasted Market Size by Region
- 4.3.1 Global Neuroendocrine Tumor Drug Sales in Volume by Region (2026-2031)
- 4.3.2 Global Neuroendocrine Tumor Drug Sales in Value by Region (2026-2031)
- 4.3.3 Global Neuroendocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2026-2031)
- 5 Neuroendocrine Tumor Drug by Application
- 5.1 Neuroendocrine Tumor Drug Market by Application
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Neuroendocrine Tumor Drug Market Size by Application
- 5.2.1 Global Neuroendocrine Tumor Drug Market Size Overview by Application (2020-2031)
- 5.2.2 Global Neuroendocrine Tumor Drug Historic Market Size Review by Application (2020-2025)
- 5.2.3 Global Neuroendocrine Tumor Drug Forecasted Market Size by Application (2026-2031)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Neuroendocrine Tumor Drug Sales Breakdown by Application (2020-2025)
- 5.3.2 Europe Neuroendocrine Tumor Drug Sales Breakdown by Application (2020-2025)
- 5.3.3 Asia-Pacific Neuroendocrine Tumor Drug Sales Breakdown by Application (2020-2025)
- 5.3.4 South America Neuroendocrine Tumor Drug Sales Breakdown by Application (2020-2025)
- 5.3.5 Middle East and Africa Neuroendocrine Tumor Drug Sales Breakdown by Application (2020-2025)
- 6 Company Profiles
- 6.1 Exelixis, Inc.
- 6.1.1 Exelixis, Inc. Comapny Information
- 6.1.2 Exelixis, Inc. Business Overview
- 6.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.1.5 Exelixis, Inc. Recent Developments
- 6.2 Foresee Pharmaceuticals, LLC
- 6.2.1 Foresee Pharmaceuticals, LLC Comapny Information
- 6.2.2 Foresee Pharmaceuticals, LLC Business Overview
- 6.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
- 6.2.5 Foresee Pharmaceuticals, LLC Recent Developments
- 6.3 Hutchison MediPharma Limited
- 6.3.1 Hutchison MediPharma Limited Comapny Information
- 6.3.2 Hutchison MediPharma Limited Business Overview
- 6.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
- 6.3.5 Hutchison MediPharma Limited Recent Developments
- 6.4 Intezyne, Inc
- 6.4.1 Intezyne, Inc Comapny Information
- 6.4.2 Intezyne, Inc Business Overview
- 6.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
- 6.4.5 Intezyne, Inc Recent Developments
- 6.5 INVENT Pharmaceuticals, Inc.
- 6.5.1 INVENT Pharmaceuticals, Inc. Comapny Information
- 6.5.2 INVENT Pharmaceuticals, Inc. Business Overview
- 6.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
- 6.6 Ipsen S.A.
- 6.6.1 Ipsen S.A. Comapny Information
- 6.6.2 Ipsen S.A. Business Overview
- 6.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
- 6.6.5 Ipsen S.A. Recent Developments
- 6.7 Karyopharm Therapeutics, Inc.
- 6.7.1 Karyopharm Therapeutics, Inc. Comapny Information
- 6.7.2 Karyopharm Therapeutics, Inc. Business Overview
- 6.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.7.5 Karyopharm Therapeutics, Inc. Recent Developments
- 6.8 Lexicon Pharmaceuticals, Inc.
- 6.8.1 Lexicon Pharmaceuticals, Inc. Comapny Information
- 6.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
- 6.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
- 6.9 Midatech Pharma Plc .
- 6.9.1 Midatech Pharma Plc . Comapny Information
- 6.9.2 Midatech Pharma Plc . Business Overview
- 6.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
- 6.9.5 Midatech Pharma Plc . Recent Developments
- 6.10 Millennium Pharmaceuticals, Inc.
- 6.10.1 Millennium Pharmaceuticals, Inc. Comapny Information
- 6.10.2 Millennium Pharmaceuticals, Inc. Business Overview
- 6.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
- 6.11 MolMed S.p.A.
- 6.11.1 MolMed S.p.A. Comapny Information
- 6.11.2 MolMed S.p.A. Business Overview
- 6.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
- 6.11.5 MolMed S.p.A. Recent Developments
- 6.12 Northwest Biotherapeutics, Inc.
- 6.12.1 Northwest Biotherapeutics, Inc. Comapny Information
- 6.12.2 Northwest Biotherapeutics, Inc. Business Overview
- 6.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.12.5 Northwest Biotherapeutics, Inc. Recent Developments
- 6.13 OctreoPharm Sciences GmbH
- 6.13.1 OctreoPharm Sciences GmbH Comapny Information
- 6.13.2 OctreoPharm Sciences GmbH Business Overview
- 6.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
- 6.13.5 OctreoPharm Sciences GmbH Recent Developments
- 6.14 OXiGENE, Inc.
- 6.14.1 OXiGENE, Inc. Comapny Information
- 6.14.2 OXiGENE, Inc. Business Overview
- 6.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 6.14.5 OXiGENE, Inc. Recent Developments
- 6.15 Jiangsu Hengrui Medicine Co., Ltd.
- 6.15.1 Jiangsu Hengrui Medicine Co., Ltd. Comapny Information
- 6.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
- 6.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
- 6.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
- 6.16 Novartis AG
- 6.16.1 Novartis AG Comapny Information
- 6.16.2 Novartis AG Business Overview
- 6.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
- 6.16.5 Novartis AG Recent Developments
- 6.17 Eisai
- 6.17.1 Eisai Comapny Information
- 6.17.2 Eisai Business Overview
- 6.17.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
- 6.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
- 6.17.5 Eisai Recent Developments
- 7 North America by Country
- 7.1 North America Neuroendocrine Tumor Drug Sales by Country
- 7.1.1 North America Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.1.2 North America Neuroendocrine Tumor Drug Sales by Country (2020-2025)
- 7.1.3 North America Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031)
- 7.2 North America Neuroendocrine Tumor Drug Market Size by Country
- 7.2.1 North America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2.2 North America Neuroendocrine Tumor Drug Market Size by Country (2020-2025)
- 7.2.3 North America Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2031)
- 8 Europe by Country
- 8.1 Europe Neuroendocrine Tumor Drug Sales by Country
- 8.1.1 Europe Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.1.2 Europe Neuroendocrine Tumor Drug Sales by Country (2020-2025)
- 8.1.3 Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031)
- 8.2 Europe Neuroendocrine Tumor Drug Market Size by Country
- 8.2.1 Europe Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2.2 Europe Neuroendocrine Tumor Drug Market Size by Country (2020-2025)
- 8.2.3 Europe Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific by Country
- 9.1 Asia-Pacific Neuroendocrine Tumor Drug Sales by Country
- 9.1.1 Asia-Pacific Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.1.2 Asia-Pacific Neuroendocrine Tumor Drug Sales by Country (2020-2025)
- 9.1.3 Asia-Pacific Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031)
- 9.2 Asia-Pacific Neuroendocrine Tumor Drug Market Size by Country
- 9.2.1 Asia-Pacific Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2.2 Asia-Pacific Neuroendocrine Tumor Drug Market Size by Country (2020-2025)
- 9.2.3 Asia-Pacific Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2031)
- 10 South America by Country
- 10.1 South America Neuroendocrine Tumor Drug Sales by Country
- 10.1.1 South America Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.1.2 South America Neuroendocrine Tumor Drug Sales by Country (2020-2025)
- 10.1.3 South America Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031)
- 10.2 South America Neuroendocrine Tumor Drug Market Size by Country
- 10.2.1 South America Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2.2 South America Neuroendocrine Tumor Drug Market Size by Country (2020-2025)
- 10.2.3 South America Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2031)
- 11 Middle East and Africa by Country
- 11.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country
- 11.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.1.2 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2020-2025)
- 11.1.3 Middle East and Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031)
- 11.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country
- 11.2.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2.2 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country (2020-2025)
- 11.2.3 Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast by Country (2026-2031)
- 12 Value Chain and Sales Channels Analysis
- 12.1 Neuroendocrine Tumor Drug Value Chain Analysis
- 12.1.1 Neuroendocrine Tumor Drug Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Neuroendocrine Tumor Drug Production Mode & Process
- 12.2 Neuroendocrine Tumor Drug Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Neuroendocrine Tumor Drug Distributors
- 12.2.3 Neuroendocrine Tumor Drug Customers
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
